Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 02, 2018 16:00 ET | Source: Novartis Pharma AG

New Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna® remain in remission almost three years after stopping therapy

ENESTop and ENESTfreedom data evaluate Treatment-free Remission (TFR) rates at 144 weeks among eligible Ph+ CML-CP patients who stopped Tasigna® Findings further support durability and safety...
June 01, 2018 08:00 ET | Source: Novartis Pharma AG

Novartis completes sale of stake in consumer healthcare joint venture to GSK for USD13.0 billion

Basel, June 1, 2018 - Novartis AG ("Novartis") today announced the completion of the divestment to GlaxoSmithKline PLC ("GSK") of its 36.5 percent stake in a consumer healthcare joint venture (JV)...
June 01, 2018 07:43 ET | Source: Novartis Pharma AG

Sandoz receives positive CHMP opinion for proposed biosimilar adalimumab

Sandoz is seeking approval of proposed biosimilar adalimumab for use in all reference medicine indications including those in rheumatology, gastroenterology and dermatology Positive CHMP opinion...
June 01, 2018 07:40 ET | Source: Novartis Pharma AG

Novartis receives positive CHMP opinion for Aimovig® (erenumab) for the prevention of migraine

If approved, Aimovig®(erenumab) is expected to be the first and only available therapy designed specifically for migraine prevention in the EU Positive opinion based on robust data package...
May 30, 2018 01:15 ET | Source: Novartis Pharma AG

FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)

Promacta receives FDA Priority Review for first-line treatment of SAA based on data showing 52% complete response rate and 85% overall response rate when added to standard immunosuppressive...
May 28, 2018 10:30 ET | Source: Novartis Pharma AG

Novartis International AG: Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto®

Overall summary score was also significantly higher for Entresto patients than for patients not taking Entresto, as measured by the 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12)[1] ...
May 24, 2018 01:00 ET | Source: Novartis Pharma AG

Sandoz receives European Commission approval for Zessly® (infliximab) in gastroenterological, rheumatological and dermatological diseases

European Commission's (EC) approval based on comprehensive data package confirming that Zessly® matches safety, efficacy and quality of reference medicine Biosimilars such as Zessly enable...
May 17, 2018 19:17 ET | Source: Novartis Pharma AG

Novartis and Amgen announce FDA approval of Aimovig(TM) (erenumab), a novel treatment developed specifically for migraine prevention

Migraine is a severe neurologic disease that profoundly impacts millions of patients in the United States Aimovig is the first and only FDA-approved treatment to block the calcitonin...
May 17, 2018 09:00 ET | Source: Novartis Pharma AG

Novartis data at ASCO and EHA reinforce company's commitment to reimagining cancer

Results from the Kisqali® MONALEESA clinical trial program, the largest industry- sponsored Phase III registration program researching a CDK4/6 inhibitor in HR+/HER2- advanced breast cancer, will...
May 16, 2018 01:15 ET | Source: Novartis Pharma AG

At the Meet Novartis Management investor event, Novartis highlights strategy to focus the company and drive sustainable growth

Full pipeline of late stage assets with blockbuster potential Positioned to deliver sales growth and margin expansion through 2022 Pipeline depth in key therapeutic areas and building new,...